GlassScriptPhysician profile
Bipin Patel
NPI 1285653931
$5,436.37
in general payments reported to CMS, 2019-2025
41 companies · $476 in 2025
The $476 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $942 · 2020: $846 · 2021: $1,071 · 2022: $501 · 2023: $538 · 2024: $1,062 · 2025: $476.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,936 · Education: $90.12 · Long Term Medical Supply Or Device Loan: $49.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,936.04 |
| Education | $90.12 |
| Long Term Medical Supply Or Device Loan | $49.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $905.88 | 2019-2025 | Airsupra, Farxiga, Lokelma |
| Glaxosmithkline, LLC. | $731.78 | 2019-2024 | Trelegy Ellipta |
| Novo Nordisk INC | $502.69 | 2019-2024 | |
| Otsuka America Pharmaceutical, INC. | $333.87 | 2019-2024 | Jynarque |
| Opko Pharmaceuticals, LLC | $300.58 | 2019-2025 | Rayaldee |
| Novartis Pharmaceuticals Corporation | $225.51 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $199.70 | 2019-2023 | Xarelto |
| Amarin Pharma, INC. | $177.67 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $160.46 | 2019-2024 | |
| Vifor Pharma, INC. | $151.15 | 2019-2023 | Veltassa |
| Fresenius USA Marketing, INC. | $150.12 | 2021-2022 | |
| Shield Therapeutics INC | $136.08 | 2023-2025 | Accrufer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $129.02 | 2019-2025 | Jardiance, Tradjenta |
| Teva Pharmaceuticals USA, INC. | $125.00 | 2024 | Uzedy |
| Lilly USA, LLC | $123.26 | 2019-2024 | Jardiance, Mounjaro |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $112.53 | 2020-2022 | |
| Abbvie INC. | $108.41 | 2021-2025 | |
| Abbott Laboratories | $72.79 | 2023-2024 | Freestyle Insulinx, Freestyle Libre 2 |
| Sumitomo Pharma America, INC. | $72.09 | 2023-2025 | Gemtesa |
| Amgen INC. | $71.52 | 2020-2025 | Tavneos, Prolia, Evenity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $55.24 | 2020-2022 | |
| Currax Pharmaceuticals LLC | $54.65 | 2021 | |
| Renalytix Ai, INC. | $52.87 | 2024-2025 | Kidneyintelx Blood Collection Convenience Kit |
| Sanofi-Aventis U.S. LLC | $50.86 | 2019-2022 | |
| Calliditas Therapeutics US INC. | $49.90 | 2022-2024 | |
| Astellas Pharma US INC | $49.88 | 2019-2022 | |
| Travere Therapeutics, INC. | $45.59 | 2022-2023 | |
| Akebia Therapeutics INC | $43.72 | 2019-2020 | |
| Seqirus USA INC | $30.59 | 2020-2025 | Fluad, Flucelvax |
| Antares Pharma, INC. | $26.13 | 2025 | Xyosted |
| Genzyme Corporation | $25.00 | 2022 | |
| Esperion Therapeutics, INC. | $24.30 | 2020 | |
| Scpharmaceuticals INC. | $17.84 | 2025 | |
| Vertical Pharmaceuticals, LLC | $17.75 | 2019 | |
| Neurocrine Biosciences, INC. | $16.81 | 2021 | |
| Dexcom, INC. | $16.76 | 2024 | Dexcom G6 Transmitter |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $15.33 | 2025 | |
| Exact Sciences Corporation | $14.71 | 2024 | Cologuard Collection Kit |
| Pfizer INC. | $14.05 | 2025 | |
| Mannkind Corporation | $13.19 | 2019 | |
| Avion Pharmaceuticals | $11.09 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bipin Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.